3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
6
Lung Neoplasms
6
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
Everolimus
6
pasireotide
5
Octreotide
5
lanreotide
2
ganitumab
2
cabozantinib
2
Bevacizumab
2
surufatinib
1
nintedanib
1
ibrutinib
1
gallium Ga 68 dotatate
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
arginyllysine
1
aflibercept
1
Temozolomide
1
TKM-080301
1
Sunitinib
1
Sorafenib
1
Somatostatin
1
Random Allocation
1
Ramucirumab
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoid Tumor
×
Immunotherapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled